Comanche Biopharma
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
50 Beharrell St Ste B, Concord, Massachu...Phone Number
(908) 432-1924Website
www.comanchebiopharma.comRevenue
$5.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Comanche Biopharma
Comanche is a biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. The company is based in Concord, MA.Explore more
Comanche Biopharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Comanche Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Comanche Biopharma recently announced quarterly report
Check if Comanche Biopharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Comanche Biopharma has new funding data
Product Launch: Get notified when Comanche Biopharma launches new products
Click to see if Comanche Biopharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Comanche Biopharma is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Comanche Biopharma
Comanche Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Comanche Biopharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to Comanche Biopharma
Compare insights from companies similar to Comanche Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Comanche Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Comanche Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Comanche Biopharma.
Comanche Biopharma financials insights
Gather financial insights about Comanche Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series B
$75M
Comanche Biopharma Tech Stack
A closer look at the technologies used by Comanche Biopharma
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Sales, Software, Safety, Pharmaceuticals, Field /Outside Sales, Artificial Intelligence, Clinical Operations, Field Marketing, Finance, Health & Safety, Healthcare Operations, Operations, Risk
Funding
Award
Award, Engineering, Product Development, Research & Development
Comanche Biopharma News & Media
Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia
Comanche Biopharma announces European Medicines Agency (EMA) has granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated preterm preeclampsia.Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
Comanche awarded Innovation Passport designation by the U.K. Innovative Licensing and Access Pathway Steering Group for CBP-4888 to treat preeclampasia.Comanche Biopharma raises $75M to fund preeclampsia drug testing
The biotech is developing an RNA-based therapy for what it describes as a root cause of the pregnancy-related complication, which affects millions of women.New Enterprise Associates Join $75 Million Series B For Comanche Biopharma
CONCORD, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) — Comanche Biopharma Corp. today announced the closing of an oversubscribed $75 million... Read More The post New Enterprise Associates Join $75 Million Series B For Comanche Biopharma appeared first on citybiz.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Comanche Biopharma
Sign Up For FreeTo access detailed company insights
Comanche is a biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. The company is based in Concord, MA.... Read More
